On 29 May 2019, the European Medicine Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for two new generics for the treatment and prevention of fungal infections, Posaconazole Accord and Posaconazole AHCL.
EMA approves two generics for fungal infections
Generics/News
|
Posted 19/07/2019
0
Post your comment
Posaconazole Accord will be available as 100 mg gastro-resistant tablets and Posaconazole AHCL will be available as a 40 mg/mL oral suspension. The active substance of both products is posaconazole, a triazole antimycotic (ATC code: J02AC04) that inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis.
Posaconazole Accord and Posaconazole AHCL are made by Accord Healthcare SLU. They are both generics of Noxafil, which has been authorized in the European Union since 25 October 2005. Studies have demonstrated the satisfactory quality of the products and their bioequivalence to the reference product. They are indicated for treatment of a number of fungal infections in adults.
Related article
Generics applications under review by EMA – January 2019
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.
Source: EMA
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment